This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Alert me on articles by topic  Social Bookmarking   What's this?

Elaine M. Hylek, MD, MPH; YuChiao Chang, PhD; Steven J. Skates, PhD; Robert A. Hughes, MD; Daniel E. Singer, MD

Arch Intern Med. 2000;160:1612-1617.

Background  Warfarin sodium therapy is highly effective in preventing thromboembolism. Its major toxic effect is hemorrhage, the risk of which increases with the international normalized ratio (INR). Data on the rate of major hemorrhage and the rate of INR decay after an episode of excessive anticoagulation therapy would help guide management of elevated INRs in the outpatient setting.

Methods  We prospectively followed up outpatients in an anticoagulant therapy unit from April 24, 1995, through March 1, 1996. Study patients had to be taking warfarin for longer than 1 month and have an INR target range of 2.0 to 3.0. Consecutive outpatients with an INR greater than 6.0 were identified and compared with a randomly selected concurrent set of patients whose INR was in the target range. Major hemorrhage was defined as fatal, intracranial, or requiring hospitalization and transfusion of at least 2 U of blood.

Results  One hundred fourteen patients with INRs greater than 6.0 were identified and compared with 268 patients with INRs in the target range. None of the patients had clinically apparent bleeding at the time of the INR measurement, and none received phytonadione (vitamin K₁). Patients did not differ significantly in age, sex, indication, or duration of warfarin therapy. Ten patients with an INR greater than 6.0 (8.8%; 95% confidence interval, 4.3%-15.5%) sought medical attention for abnormal bleeding, and 5 of these experienced a major hemorrhage during 14-day follow-up (4.4%; 95% confidence interval, 1.4%-9.9%) compared with none of the patients with an in-range INR (P<.001). Thirty-three percent of patients with INRs greater than 6.0 had INRs less than 4.0 within 24 hours, 55% within 48 hours, 73% within 72 hours, and nearly 90% within 96 hours of temporary discontinuation of warfarin therapy.

Conclusions  Outpatients with INRs greater than 6.0 face a significant short-term risk of major hemorrhage. Randomized trials are needed to determine the net benefit of preventive treatment with phytonadione.

From the General Medicine Division/Clinical Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(11):1708-1709.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
Ellis et al.
Circulation 2009;120:1029-1035.
ABSTRACT | FULL TEXT  

Vitamin K to Correct Overanticoagulation
Jindeel
ANN INTERN MED 2009;151:434-434.
FULL TEXT  

Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin: A Randomized Trial
Crowther et al.
ANN INTERN MED 2009;150:293-300.
ABSTRACT | FULL TEXT  

Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients: The LIFE Study
Okin et al.
Circ Arrhythm Electrophysiol 2008;1:337-343.
ABSTRACT | FULL TEXT  

Management of Excessive Anticoagulant Effect Due to Vitamin K Antagonists
Dentali and Crowther
ASH Education Book 2008;2008:266-270.
ABSTRACT | FULL TEXT  

Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare
Kristoffersen et al.
Clin. Chem. 2006;52:1871-1878.
ABSTRACT | FULL TEXT  

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Okin et al.
JAMA 2006;296:1242-1248.
ABSTRACT | FULL TEXT  

Comparison of outcomes using 2 delivery models of anticoagulation care.
Staresinic et al.
Arch Intern Med 2006;166:997-1002.
ABSTRACT | FULL TEXT  

Validity of Criteria Used to Evaluate Fingerstick Devices That Assess International Normalized Ratio
Shermock et al.
Med Decis Making 2006;26:239-246.
ABSTRACT  

Prothrombin time testing practices: adherence to guidelines and standards.
Shahangian et al.
Clin. Chem. 2006;52:793-794.
FULL TEXT  

Treatment of Excessive Anticoagulation With Phytonadione (Vitamin K): A Meta-analysis.
DeZee et al.
Arch Intern Med 2006;166:391-397.
ABSTRACT | FULL TEXT  

The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy
Garcia et al.
J Am Coll Cardiol 2006;47:804-808.
ABSTRACT | FULL TEXT  

Search for Predictors of Nontherapeutic INR Results with Warfarin Therapy
McGriff-Lee et al.
The Annals of Pharmacotherapy 2005;39:1996-2002.
ABSTRACT | FULL TEXT  

A Randomized Trial Comparing 1 mg of Oral Vitamin K With No Treatment in the Management of Warfarin-Associated Coagulopathy in Patients With Mechanical Heart Valves
Ageno et al.
J Am Coll Cardiol 2005;46:732-733.
FULL TEXT  

Initiating Warfarin Therapy: 5 mg versus 10 mg
Eckhoff et al.
The Annals of Pharmacotherapy 2004;38:2115-2121.
ABSTRACT | FULL TEXT  

International Normalized Ratio Increase Before Warfarin-Associated Hemorrhage: Brief and Subtle
Kucher et al.
Arch Intern Med 2004;164:2176-2179.
ABSTRACT | FULL TEXT  

Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study
Lloyd-Jones et al.
Circulation 2004;110:1042-1046.
ABSTRACT | FULL TEXT  

The Effect of Excessive Anticoagulation on Mortality and Morbidity in Hospitalized Patients With Anticoagulant-Related Major Hemorrhage
Koo et al.
Arch Intern Med 2004;164:1557-1560.
ABSTRACT | FULL TEXT  

Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis
Linkins et al.
ANN INTERN MED 2003;139:893-900.
ABSTRACT | FULL TEXT  

Comparison of Oral vs Intravenous Phytonadione (Vitamin K1) in Patients With Excessive Anticoagulation: A Prospective Randomized Controlled Study
Lubetsky et al.
Arch Intern Med 2003;163:2469-2473.
ABSTRACT | FULL TEXT  

Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate
Deveras and Kessler
ANN INTERN MED 2002;137:884-888.
ABSTRACT | FULL TEXT  

Oral anticoagulation and risk of death: a medical record linkage study
Oden and Fahlen
BMJ 2002;325:1073-1075.
ABSTRACT | FULL TEXT  

A Survey of Oral Vitamin K Use by Anticoagulation Clinics
Libby and Garcia
Arch Intern Med 2002;162:1893-1896.
ABSTRACT | FULL TEXT  

Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy: A Randomized, Controlled Trial
Crowther et al.
ANN INTERN MED 2002;137:251-254.
ABSTRACT | FULL TEXT  

Update in Hematology
Catlett and Alving
ANN INTERN MED 2002;136:136-143.
FULL TEXT  

Treatment of Warfarin-Associated Coagulopathy : A Physician Survey
Wilson et al.
Chest 2001;120:1972-1976.
ABSTRACT | FULL TEXT  

Managing Excessive Warfarin Anticoagulation
Bussey
ANN INTERN MED 2001;135:460-462.
FULL TEXT  

Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation
Gage et al.
ANN INTERN MED 2001;134:465-474.
ABSTRACT | FULL TEXT  

Anticoagulation Therapy
Ginsberg et al.
ASH Education Book 2001;2001:339-357.
ABSTRACT | FULL TEXT